questionsmedicales.fr
Enzymes et coenzymes
Enzymes
Hydrolases
Glycosidases
Sialidase
Sialidase : Questions médicales fréquentes
Termes MeSH sélectionnés :
Angiotensin Receptor Antagonists
Diagnostic
5
Sialidase
Diagnostic médical
Neuraminidase
Tests diagnostiques
Sialidase
Génétique médicale
Symptômes
5
Sialidase
Troubles neurologiques
Sialidase
Éruptions cutanées
Sialidase
Troubles de la vision
Prévention
5
Sialidase
Dépistage prénatal
Sialidase
Conseils génétiques
Traitements
5
Sialidase
Traitement symptomatique
Sialidase
Thérapie génique
Sialidase
Essais cliniques
Complications
5
Sialidase
Troubles mentaux
Facteurs de risque
5
Sialidase
Facteurs de risque
Sialidase
Mutations génétiques
Sialidase
Antécédents médicaux
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Sialidase : Questions médicales les plus fréquentes",
"headline": "Sialidase : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Sialidase : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-13",
"dateModified": "2025-04-07",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Sialidase"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Glycosidases",
"url": "https://questionsmedicales.fr/mesh/D006026",
"about": {
"@type": "MedicalCondition",
"name": "Glycosidases",
"code": {
"@type": "MedicalCode",
"code": "D006026",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.277.450"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Sialidase",
"alternateName": "Neuraminidase",
"code": {
"@type": "MedicalCode",
"code": "D009439",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Yong Chong",
"url": "https://questionsmedicales.fr/author/Yong%20Chong",
"affiliation": {
"@type": "Organization",
"name": "Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan."
}
},
{
"@type": "Person",
"name": "Hideyuki Ikematsu",
"url": "https://questionsmedicales.fr/author/Hideyuki%20Ikematsu",
"affiliation": {
"@type": "Organization",
"name": "Japan Physicians Association, Influenza Study Group, Tokyo, Japan."
}
},
{
"@type": "Person",
"name": "Muchtaridi Muchtaridi",
"url": "https://questionsmedicales.fr/author/Muchtaridi%20Muchtaridi",
"affiliation": {
"@type": "Organization",
"name": "Functional Nano Powder University Center of Excellence (FiNder U CoE), Universitas Padjadajaran, Jl. Bandung-Sumedang KM 21, Jatinangor 45363, Indonesia."
}
},
{
"@type": "Person",
"name": "Amirah Mohd Gazzali",
"url": "https://questionsmedicales.fr/author/Amirah%20Mohd%20Gazzali",
"affiliation": {
"@type": "Organization",
"name": "School of Pharmaceutical Sciences, Universiti Sains Malaysia, Minden 11800, Malaysia."
}
},
{
"@type": "Person",
"name": "Habibah A Wahab",
"url": "https://questionsmedicales.fr/author/Habibah%20A%20Wahab",
"affiliation": {
"@type": "Organization",
"name": "School of Pharmaceutical Sciences, Universiti Sains Malaysia, Minden 11800, Malaysia."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Synthesis, Characterization and Application of a MIP-polyHIPE for Selective Extraction of Angiotensin II Receptor Antagonists Residues in Natural Waters.",
"datePublished": "2023-03-10",
"url": "https://questionsmedicales.fr/article/36981793",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijerph20064878"
}
},
{
"@type": "ScholarlyArticle",
"name": "Angiotensin receptor blocker use is associated with upregulation of the memory-protective angiotensin type 4 receptor (AT",
"datePublished": "2022-08-15",
"url": "https://questionsmedicales.fr/article/35969296",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s11357-022-00639-8"
}
},
{
"@type": "ScholarlyArticle",
"name": "Decoding Angiotensin Receptors: TOMAHAQ-Based Detection and Quantification of Angiotensin Type-1 and Type-2 Receptors.",
"datePublished": "2023-09-08",
"url": "https://questionsmedicales.fr/article/37681524",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1161/JAHA.123.030791"
}
},
{
"@type": "ScholarlyArticle",
"name": "Kidney Outcomes Following Angiotensin Receptor-Neprilysin Inhibitor vs Angiotensin-Converting Enzyme Inhibitor/Angiotensin Receptor Blocker Therapy for Thrombotic Microangiopathy.",
"datePublished": "2024-09-03",
"url": "https://questionsmedicales.fr/article/39264627",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1001/jamanetworkopen.2024.32862"
}
},
{
"@type": "ScholarlyArticle",
"name": "Network Meta-Analysis Comparing Angiotensin Receptor-Neprilysin Inhibitors, Angiotensin Receptor Blockers, and Angiotensin-Converting Enzyme Inhibitors in Heart Failure With Reduced Ejection Fraction.",
"datePublished": "2022-11-29",
"url": "https://questionsmedicales.fr/article/36459752",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.amjcard.2022.10.026"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Enzymes et coenzymes",
"item": "https://questionsmedicales.fr/mesh/D045762"
},
{
"@type": "ListItem",
"position": 3,
"name": "Enzymes",
"item": "https://questionsmedicales.fr/mesh/D004798"
},
{
"@type": "ListItem",
"position": 4,
"name": "Hydrolases",
"item": "https://questionsmedicales.fr/mesh/D006867"
},
{
"@type": "ListItem",
"position": 5,
"name": "Glycosidases",
"item": "https://questionsmedicales.fr/mesh/D006026"
},
{
"@type": "ListItem",
"position": 6,
"name": "Sialidase",
"item": "https://questionsmedicales.fr/mesh/D009439"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Sialidase - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Sialidase",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-18",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Sialidase",
"description": "Comment diagnostiquer une déficience en sialidase ?\nQuels tests sont utilisés pour détecter la neuraminidase ?\nQuels symptômes indiquent une anomalie de sialidase ?\nLa sialidase est-elle mesurable dans le sang ?\nQuels spécialistes peuvent diagnostiquer une déficience en sialidase ?",
"url": "https://questionsmedicales.fr/mesh/D009439?mesh_terms=Angiotensin+Receptor+Antagonists#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Sialidase",
"description": "Quels sont les symptômes d'une déficience en sialidase ?\nLa déficience en sialidase cause-t-elle des douleurs ?\nY a-t-il des signes cutanés associés à la sialidase ?\nLes troubles de la vision sont-ils liés à la sialidase ?\nLes symptômes de sialidase varient selon l'âge ?",
"url": "https://questionsmedicales.fr/mesh/D009439?mesh_terms=Angiotensin+Receptor+Antagonists#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Sialidase",
"description": "Peut-on prévenir les déficiences en sialidase ?\nLe dépistage prénatal est-il possible pour la sialidase ?\nLes conseils génétiques sont-ils recommandés ?\nLes vaccinations peuvent-elles influencer la sialidase ?\nY a-t-il des facteurs environnementaux à surveiller ?",
"url": "https://questionsmedicales.fr/mesh/D009439?mesh_terms=Angiotensin+Receptor+Antagonists#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Sialidase",
"description": "Quel est le traitement principal pour la déficience en sialidase ?\nDes thérapies géniques sont-elles disponibles pour la sialidase ?\nLes médicaments peuvent-ils aider à gérer les symptômes ?\nLa physiothérapie est-elle bénéfique pour les patients ?\nY a-t-il des traitements expérimentaux pour la sialidase ?",
"url": "https://questionsmedicales.fr/mesh/D009439?mesh_terms=Angiotensin+Receptor+Antagonists#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Sialidase",
"description": "Quelles complications peuvent survenir avec la sialidase ?\nLa sialidase peut-elle entraîner des troubles mentaux ?\nY a-t-il un risque accru d'infections ?\nLes complications sont-elles réversibles ?\nLes complications varient-elles selon l'âge ?",
"url": "https://questionsmedicales.fr/mesh/D009439?mesh_terms=Angiotensin+Receptor+Antagonists#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Sialidase",
"description": "Quels sont les facteurs de risque pour la sialidase ?\nLa consanguinité augmente-t-elle le risque de sialidase ?\nLes mutations génétiques sont-elles un facteur de risque ?\nLes facteurs environnementaux influencent-ils la sialidase ?\nLes antécédents médicaux familiaux sont-ils importants ?",
"url": "https://questionsmedicales.fr/mesh/D009439?mesh_terms=Angiotensin+Receptor+Antagonists#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une déficience en sialidase ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un diagnostic se fait par des tests enzymatiques et des analyses génétiques."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour détecter la neuraminidase ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests enzymatiques et des biopsies tissulaires peuvent être utilisés."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent une anomalie de sialidase ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme des troubles neurologiques et des anomalies de développement peuvent apparaître."
}
},
{
"@type": "Question",
"name": "La sialidase est-elle mesurable dans le sang ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des niveaux d'activité de sialidase peuvent être mesurés dans le sérum."
}
},
{
"@type": "Question",
"name": "Quels spécialistes peuvent diagnostiquer une déficience en sialidase ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des généticiens et des pédiatres spécialisés en métabolisme peuvent poser le diagnostic."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une déficience en sialidase ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des retards de développement, des troubles neurologiques et des problèmes oculaires."
}
},
{
"@type": "Question",
"name": "La déficience en sialidase cause-t-elle des douleurs ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut entraîner des douleurs dues à des complications neurologiques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des signes cutanés associés à la sialidase ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des éruptions cutanées peuvent survenir, mais ce n'est pas systématique."
}
},
{
"@type": "Question",
"name": "Les troubles de la vision sont-ils liés à la sialidase ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles visuels peuvent être observés chez certains patients."
}
},
{
"@type": "Question",
"name": "Les symptômes de sialidase varient selon l'âge ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent évoluer avec l'âge et la gravité de la déficience."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les déficiences en sialidase ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de mesures préventives spécifiques pour cette condition."
}
},
{
"@type": "Question",
"name": "Le dépistage prénatal est-il possible pour la sialidase ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le dépistage génétique peut être proposé aux familles à risque."
}
},
{
"@type": "Question",
"name": "Les conseils génétiques sont-ils recommandés ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les conseils génétiques sont importants pour les familles concernées."
}
},
{
"@type": "Question",
"name": "Les vaccinations peuvent-elles influencer la sialidase ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, les vaccinations n'ont pas d'impact sur la déficience en sialidase."
}
},
{
"@type": "Question",
"name": "Y a-t-il des facteurs environnementaux à surveiller ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, aucun facteur environnemental n'est clairement lié à la sialidase."
}
},
{
"@type": "Question",
"name": "Quel est le traitement principal pour la déficience en sialidase ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de traitement curatif, mais des soins symptomatiques sont proposés."
}
},
{
"@type": "Question",
"name": "Des thérapies géniques sont-elles disponibles pour la sialidase ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des recherches sont en cours, mais aucune thérapie génique n'est encore approuvée."
}
},
{
"@type": "Question",
"name": "Les médicaments peuvent-ils aider à gérer les symptômes ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des médicaments peuvent être prescrits pour gérer les symptômes neurologiques."
}
},
{
"@type": "Question",
"name": "La physiothérapie est-elle bénéfique pour les patients ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la physiothérapie peut aider à améliorer la mobilité et la qualité de vie."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements expérimentaux pour la sialidase ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des essais cliniques sont en cours pour explorer de nouveaux traitements."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec la sialidase ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications neurologiques, cardiaques et respiratoires peuvent se développer."
}
},
{
"@type": "Question",
"name": "La sialidase peut-elle entraîner des troubles mentaux ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles mentaux peuvent être associés à des déficiences neurologiques."
}
},
{
"@type": "Question",
"name": "Y a-t-il un risque accru d'infections ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les patients peuvent avoir un risque accru d'infections respiratoires."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées, mais beaucoup ne sont pas réversibles."
}
},
{
"@type": "Question",
"name": "Les complications varient-elles selon l'âge ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les complications peuvent varier en fonction de l'âge et de la gravité de la maladie."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour la sialidase ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents familiaux de maladies génétiques augmentent le risque."
}
},
{
"@type": "Question",
"name": "La consanguinité augmente-t-elle le risque de sialidase ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la consanguinité peut augmenter le risque de transmission de gènes défectueux."
}
},
{
"@type": "Question",
"name": "Les mutations génétiques sont-elles un facteur de risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des mutations dans le gène NEU1 sont souvent responsables de la déficience."
}
},
{
"@type": "Question",
"name": "Les facteurs environnementaux influencent-ils la sialidase ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, aucun facteur environnemental n'est clairement identifié comme influent."
}
},
{
"@type": "Question",
"name": "Les antécédents médicaux familiaux sont-ils importants ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les antécédents médicaux familiaux peuvent aider à évaluer le risque."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 07/04/2025
Contenu vérifié selon les dernières recommandations médicales
4 publications dans cette catégorie
Affiliations :
Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.
Publications dans "Sialidase" :
4 publications dans cette catégorie
Affiliations :
Japan Physicians Association, Influenza Study Group, Tokyo, Japan.
Publications dans "Sialidase" :
3 publications dans cette catégorie
Affiliations :
Functional Nano Powder University Center of Excellence (FiNder U CoE), Universitas Padjadajaran, Jl. Bandung-Sumedang KM 21, Jatinangor 45363, Indonesia.
Department of Pharmaceutical Analysis and Medicinal Chemistry, Faculty of Pharmacy, Universitas Padjadjaran, Jl. Bandung-Sumedang KM 21, Jatinangor 45363, Indonesia.
Publications dans "Sialidase" :
3 publications dans cette catégorie
Affiliations :
School of Pharmaceutical Sciences, Universiti Sains Malaysia, Minden 11800, Malaysia.
Publications dans "Sialidase" :
3 publications dans cette catégorie
Affiliations :
School of Pharmaceutical Sciences, Universiti Sains Malaysia, Minden 11800, Malaysia.
Publications dans "Sialidase" :
3 publications dans cette catégorie
Affiliations :
School of Chemical and Environmental Engineering, Shanghai Institute of Technology, Shanghai, 201418, China. Electronic address: chengliping@sit.edu.cn.
Publications dans "Sialidase" :
3 publications dans cette catégorie
Affiliations :
Japan Physicians Association, Tokyo, Japan.
Publications dans "Sialidase" :
3 publications dans cette catégorie
Affiliations :
Japan Physicians Association, Tokyo, Japan.
Publications dans "Sialidase" :
3 publications dans cette catégorie
Affiliations :
Department of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
Publications dans "Sialidase" :
3 publications dans cette catégorie
Affiliations :
College of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan, China.
Publications dans "Sialidase" :
3 publications dans cette catégorie
Affiliations :
State Key Laboratory of Natural Medicines, China Pharmaceutical University, No. 24 Tongjia Lane, Nanjing 210009, China.
School of Traditional Chinese Pharmacy, China Pharmaceutical University, No. 639 Longmian Road, Nanjing 211198, China.
Publications dans "Sialidase" :
3 publications dans cette catégorie
Affiliations :
State Key Laboratory of Natural Medicines, China Pharmaceutical University, No. 24 Tongjia Lane, Nanjing 210009, China.
School of Traditional Chinese Pharmacy, China Pharmaceutical University, No. 639 Longmian Road, Nanjing 211198, China.
Publications dans "Sialidase" :
3 publications dans cette catégorie
Affiliations :
Department of Chemistry, University of Alberta, Edmonton, Alberta, Canada.
Publications dans "Sialidase" :
3 publications dans cette catégorie
Affiliations :
Department of Chemistry, University of Alberta, Edmonton, Alberta, Canada.
Publications dans "Sialidase" :
3 publications dans cette catégorie
Affiliations :
Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Publications dans "Sialidase" :
2 publications dans cette catégorie
Affiliations :
a Department of Biotechnology , Faculty of Natural Sciences of University Ss. Cyril and Methodius , Trnava , Slovakia.
Publications dans "Sialidase" :
2 publications dans cette catégorie
Affiliations :
a Department of Biotechnology , Faculty of Natural Sciences of University Ss. Cyril and Methodius , Trnava , Slovakia.
c International Centre for Applied Research and Sustainable Technology , Bratislava , Slovakia.
Publications dans "Sialidase" :
2 publications dans cette catégorie
Affiliations :
Scientific and Educational Center Molecular Bases of Interaction of Microorganisms and Human of the World-Class Research Center Center for Personalized Medicine of Federal State Budgetary Scientific Institution "Institute of Experimental Medicine", Saint Petersburg 197376, Russia.
Publications dans "Sialidase" :
2 publications dans cette catégorie
Affiliations :
Scientific and Educational Center Molecular Bases of Interaction of Microorganisms and Human of the World-Class Research Center Center for Personalized Medicine of Federal State Budgetary Scientific Institution "Institute of Experimental Medicine", Saint Petersburg 197376, Russia.
Publications dans "Sialidase" :
2 publications dans cette catégorie
Affiliations :
Medical Center, St. Petersburg Research Institute of Epidemiology and Microbiology Named after Pasteur, Saint Petersburg 197101, Russia.
Publications dans "Sialidase" :
Polymers via high internal phase emulsion (polyHIPEs) were molecularly imprinted with Irbesartan, an antihypertensive drug belonging to the class of angiotensin II receptor antagonists (sartan drugs),...
The reported primary dementia-protective benefits of angiotensin II type 1 receptor (AT...
Background The renin-angiotensin system plays a crucial role in human physiology, and its main hormone, angiotensin, activates 2 G-protein-coupled receptors, the angiotensin type-1 and type-2 receptor...
Thrombotic microangiopathy (TMA) on kidney biopsy is a pattern of endothelial injury commonly seen in malignant hypertension (mHTN), but treatment strategies are not well established....
To evaluate the kidney outcomes of angiotensin receptor-neprilysin inhibitor (ARNI), specifically sacubitril/valsartan, vs angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocke...
This single-center cohort study enrolled consecutive patients in China diagnosed with mHTN-associated TMA through kidney biopsy from January 2008 to June 2023. Follow-up was conducted until the conclu...
Treatment with sacubitril/valsartan or ACEI/ARBs during hospitalization and after discharge....
The primary outcome was a composite of kidney recovery: a 50% decrease in serum creatinine level, decrease in serum creatinine levels to the reference range, or kidney survival free from dialysis for ...
Among the 217 patients (mean [SD] age, 35.9 [8.8] years; 188 men [86.6%]) included in the study, 66 (30.4%) received sacubitril/valsartan and 151 (69.6%) received ACEI/ARBs at baseline. Sacubitril/val...
In this cohort study, sacubitril/valsartan treatment was associated with a potential kidney function benefit in patients with mHTN-associated TMA compared with ACEI/ARB treatment. The findings suggest...
The superiority of angiotensin receptor-neprilysin inhibitor (ARNI) over angiotensin-converting enzyme inhibitor (ACE-I) and angiotensin receptor blocker (ARB) has not been reassessed after the public...
Medications used to treat hypertension may affect fracture risk. This study investigated fracture risk for users of angiotensin converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers ...
Angiotensin receptor blockers (ARBs) used in the treatment of hypertension and potentially in SARS-CoV-2 infection exhibit inverse agonist effects at angiotensin AR1 receptors, suggesting the receptor...
The aim of this study was to conduct a systematic review and meta-analysis to investigate the effect of the premorbid use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blocker...
Embase, the Cochrane Central Register of Controlled Trials, and MEDLINE were searched for studies based on the below eligibility criteria. The protocol was registered at the PROSPERO (CRD42022309129)....
Eligibility criteria were as follows: (1) randomized controlled trials, cohort studies, cross-sectional studies, (2) patients with sepsis aged ≥16 years, and (3) received premorbid ACEI/ARB, or not....
The patient and study characteristics and outcomes were extracted. All analyses were presented with the use of random-effects models. The primary outcome was short-term mortality defined as ≤30-day, i...
Fifteen studies (N = 96,159) met the eligibility criteria. Of these, eleven studies (N = 40,360) reported unadjusted short-term mortalities. The pooled odds ratio (OR) of short-term mortality with the...
In this meta-analysis, the premorbid ACEI/ARB was associated with significantly lower short-term mortality in patients with sepsis despite the significantly higher risk of AKI....
Guidelines suggest that adults with diabetes and kidney disease receive treatment with angiotensin-converting-enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB). This is an update of a Co...
We compared the efficacy and safety of ACEi and ARB therapy (either as monotherapy or in combination) on cardiovascular and kidney outcomes in adults with diabetes and kidney disease....
We searched the Cochrane Kidney and Transplants Register of Studies to 17 March 2024 through contact with the Information Specialist using search terms relevant to this review. Studies in the Register...
We included studies evaluating ACEi or ARB alone or in combination, compared to each other, placebo or no treatment in people with diabetes and kidney disease....
Two authors independently assessed the risk of bias and extracted data. Summary estimates of effect were obtained using a random-effects model, and results were expressed as risk ratios (RR) and their...
One hundred and nine studies (28,341 randomised participants) were eligible for inclusion. Overall, the risk of bias was high. Compared to placebo or no treatment, ACEi may make little or no differenc...
ACEi or ARB may make little or no difference to all-cause and cardiovascular death compared to placebo or no treatment in people with diabetes and kidney disease but may prevent kidney failure. ARB ma...
For persons with proteinuria, angiotensin-converting enzyme inhibitors (ACEis) and angiotensin II receptor blockers (ARBs) are treatment mainstays for reducing kidney disease progression. Guidelines f...